Fig. 6.

TREM2 regulates MAPK-p38 and PPARγ phosphorylation. a–d Representative Western blots and normalized ratios of p-p38:t-p38, p-JNK1/2:t-JNK1/2, p-ERK1/2:t-ERK1/2, and p-PPARγ:t-PPARγ in RAW264.7 cells or mSMCs infected with LV-GFP or LV-TREM2 group (n = 6/group, student’s t test). e, f Representative images of ORO- and DiI-oxLDL-positive areas in Raw264.7 cells or mSMCs obtained from the indicated group. Nuclei were stained with DAPI (blue). RAW264.7 cells and mSMCs were cultured with the p38 phosphorylation agonist dehydrocorydaline (Deh) before oxLDL or DiI-oxLDL stimulation, and then the ORO- or DiI-oxLDL-positive area was analyzed (n = 6–9/group, two-way ANOVA followed by a post hoc Tukey’s test). g, h Immunoblot analysis of the expression of p-p38, t-p38, p-PPARγ, t-PPARγ, and CD36 in RAW264.7 cells and mSMCs treated with dehydrocorydaline (Deh) or an equal volume of DMSO (ctr, n = 6/group, two-way ANOVA test followed by a post hoc Tukey’s test). Quantitative data represent the fold change observed after normalizing the indicated protein band intensities to GAPDH. All data are presented as the mean ± SEM from three to five independent experiments. Scale bar: 10 μm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. mFI mean fluorescence intensity. Deh, dehydrocorydaline